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Abstract
MicroRNAs (miRNAs) are small noncoding RNAs which play essential roles in many important biological processes.
Therefore, their dysfunction is associated with a variety of human diseases, including cancer. Increasing evidence shows that
miRNAs can act as oncogenes or tumor suppressors, and although there is great interest in research into these cancer-
associated miRNAs, little is known about them. In this study, we performed a comprehensive analysis of putative human
miRNA oncogenes and tumor suppressors. We found that miRNA oncogenes and tumor suppressors clearly show different
patterns in function, evolutionary rate, expression, chromosome distribution, molecule size, free energy, transcription
factors, and targets. For example, miRNA oncogenes are located mainly in the amplified regions in human cancers, whereas
miRNA tumor suppressors are located mainly in the deleted regions. miRNA oncogenes tend to cleave target mRNAs more
frequently than miRNA tumor suppressors. These results indicate that these two types of cancer-associated miRNAs play
different roles in cancer formation and development. Moreover, the patterns identified here can discriminate novel miRNA
oncogenes and tumor suppressors with a high degree of accuracy. This study represents the first large-scale bioinformatic
analysis of human miRNA oncogenes and tumor suppressors. Our findings provide help for not only understanding of
miRNAs in cancer but also for the specific identification of novel miRNAs as miRNA oncogenes and tumor suppressors. In
addition, the data presented in this study will be valuable for the study of both miRNAs and cancer.
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Introduction
MicroRNAs (miRNAs) are recently identified endogenous small
non-coding regulatory RNAs (,22 nt) [1,2]. miRNA genes are
transcribed as primary miRNA precursors (pri-miRNAs), which
are converted into ,100 bp precursor miRNAs (pre-miRNAs).
These pre-miRNAs are further processed into ,22 bp mature
miRNAs which can exert regulatory function on target genes [3].
miRNAs normally function as negative gene regulators at the post-
transcriptional level by binding to the 39UTRs of the target
mRNA through base pairing, resulting in its cleavage or
translation inhibition [4,5,6]. Increasing evidence indicates that
miRNAs play crucial roles in a variety of basic biological
processes, such as metabolism, proliferation, development [7,8],
differentiation [9], apoptosis [10,11,12], cellular signaling [13],
and immune response [14].
Emerging evidence also shows that dysfunction of miRNAs is
associated with various human diseases, such as cardiovascular
disease and cancer [7,8]. It is well known that cancer is
associated with very complex genetic alternations in oncogenes
and tumor suppressors [7,15]. And recent evidence shows that
miRNAs also contribute to tumor formation and development,
suggesting that miRNAs can function as oncogenes or tumor
suppressors [7,15,16,17,18]. Moreover, these tumor associated
miRNAs can serve as biomarkers for tumor diagnosis and
prognosis [17] or therapeutic targets [7,15]. Although the
emergence of miRNAs as oncogenes and tumor suppressors
has attracted great interest, little is known about these miRNAs.
Therefore, it is of particular importance to investigate miRNA
oncogenes and tumor suppressors on a large scale basis in order
to improve our understanding of miRNAs and their relationship
with cancer.
To accomplish this, wefocushereonagroupofhumanmiRNA
oncogenes (referred to as p-oncomirs) and tumor suppressors
(referred to as p-mirsupps), and evaluate the function, evolution-
ary conservation, chromosome distribution, expression, molecule
size, free energy, transcription factors, and targets of these
molecules. Finally, a machine-learning based prediction model is
established for use in discriminating novel human miRNA
oncogenes from tumor suppressors. Our results not only present
clear patterns capable of discriminating p-oncomirs from p-
mirsupps, butalsoprovide newinsights intothe role of miRNAs in
cancer, which is of potential value in cancer diagnosis, prognosis
and therapy.
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e13067Results
Functions of p-oncomirs and p-mirsupps
In order to summarize the functions of p-oncomirs and p-
mirsupps, a miRNA function database [19] and related literature
were manually culled and reviewed. As a result, the functions of p-
oncomirs and p-mirsupps can be thought of as representing two
basic complementary processes of cancer formation and develop-
ment, namely oncogenesis and tumor-suppression (File S1). The
p-oncomirs typically function to promote cell growth, inhibit
apoptosis, repress immune cell development and control the cell
cycle, while p-mirsupps function to inhibit cell growth, induce
apoptosis, regulate immune cell development, and bring about cell
cycle arrest. In addition, miRNA oncogenes and tumor suppres-
sors are not invariable in function but can perform the converse
function (oncogene becomes suppressor and vice versa) under
specific conditions. For example, as a miRNA oncogene, mir-24
normally functions to promote lung carcinoma cell growth as
reported by Cheng et al [20]. However, they also reported that
inhibition of mir-24 resulted in a profound increase in Hela cell
growth, representing an aspect of tumor-suppression [20].
Evolutionary conservation of p-oncomirs and p-mirsupps
The evolutionary conservation of genes has important implica-
tions in the study of gene function, genomic organization, human
disease, and medicine [21,22]. Many miRNAs are also conserved
in various species during evolution [23,24,25], but some miRNAs
show evidence of rapid evolution [26,27]. It has been reported that
the importance of a gene is negatively correlated with its
evolutionary rate [28], and as guardians of the genome, loss-
function of tumor suppressors may be more critical in tumorigen-
esis, as demonstrated by Cui et al. [29]. However, the evolutionary
patterns of p-oncomirs and p-mirsupps are largely unclear.
Therefore, in order to determine the evolutionary patterns of p-
oncomirs and p-mirsupps, we studied several aspects of their
evolution including cross species conservation, miRNA gene
duplicates, and single nucleotide polymorphisms (SNPs).
1. Cross-species conservation. We investigated the cross-
species distribution of human p-oncomirs and p-mirsupps. To do
so, we classified human miRNAs into five groups based on the
miRNA family data in miRBase [30] using the method of Zhang
et al. (File S2) [26]. These groups include miRNAs that are
present only in humans (G5); miRNAs that are conserved in
primates (G4); conserved in mammals (G3); conserved in
vertebrates (G2); or conserved in other more distant species (G1,
which is the most conserved group). We found that the distribution
of p-oncomirs, p-mirsupps, and other miRNAs (referred to as o-
miRNAs) was markedly uneven in these five groups (Figure 1).
The t-oncomirs (p-oncomirs and p-mirsupps referred to as tumor-
associated miRNAs) were more conserved than o-miRNAs. More
than 96.8% (61/63) of the t-miRNAs were present in the G1 or
G2 groups, which was significantly higher than the presence of o-
miRNAs (21.3%, 137/643) (P=1.16610
234, Fisher’s exact test,
Figure S1a). This result indicates that t-miRNAs may be of
greater importance in molecular functions and biological
processes, or conversely, that dysfunction of these molecules has
a greater probability of causing cancer. In addition, p-mirsupps
showed significantly higher conservation than p-oncomirs, and
almost 62.2% of the p-mirsupps were conserved in the G1 group,
while only 11.5% of the p-oncomirs were conserved in the G1
group (P=5.0610
25, Fisher’s exact test, Figure S1b). This result
suggests that analogous to the tumor suppressors of protein coding
genes, these miRNA tumor suppressors may also be more critical
in regulating tumorigenesis than miRNA oncogenes.
2. Identical miRNA duplicates. Gene duplication is one of
the most important mechanisms of gene function compensation,
wherein, loss-of-function in one gene can be compensated by its
duplicate(s) [31]. Many protein-coding genes have duplicates, and
deletion of one gene in a set of duplicates is typically less critical
than deletion of a singleton gene, as Gu et al. demonstrated in
yeast [31]. It is therefore possible that a given gene needs
duplicates as it is essential in such a way that an additional copy is
required to ensure a low lethality if loss-of-function occurs in this
gene [32]. Some reports have shown that duplicated genes evolve
more slowly than singletons [33], which suggests that conserved
(important) genes have a greater probability of having duplicates.
This in turn raises the question as to whether this biologic pattern
is also found among miRNAs. Some miRNA genes are distinctly
different in situ but have identical mature sequences, termed as
identical miRNA duplicates in this study. However, the
distribution of identical miRNA duplicate in p-oncomirs and p-
mirsupps is unclear, and which among the four groups, t-miRNAs,
o-miRNAs, p-oncomirs, and p-mirsupps has greatest incidence of
identical miRNA duplicates is unknown. Based on our analysis of
miRNAs cross-species conservation, we expected that t-miRNAs
would have a greater identical duplicate incidence as compared
with o-miRNAs, and p-mirsupps would likely have a greater
duplicate incidence than p-oncomirs. As expected, p-mirsupps
have the highest duplicate incidence (28.6%, 8/28), followed by p-
mirsupps (12.5%, 3/24) and o-miRNAs (9.0%, 51/567). These
miRNAs thus show significantly different incidences of identical
duplicates (P=0.003, chi-square test, Figure S1c). The odds-ratio
(OR) of t-miRNAs versus o-miRNAs is 2.35 and the OR of p-
mirsupps versus p-oncomirs is 2.29. This is the first report to show
that tumor-associated miRNAs tend to have a higher duplicate
incidence than other miRNAs, and of it is of note that miRNA
tumor suppressors tend to have a higher duplicate incidence than
miRNA oncogenes.
3. SNPs of p-oncomirs and p-mirsupps. Conserved genes
tend to have a low frequency of SNPs, and as the most common
genetic variants in the human genome [34,35], SNPs can be used
Figure 1. Heatmap of human miRNAs (rows) conserved across
five species groups (columns). If a given miRNA is present in the
corresponding conservation group, the corresponding element in the
heatmap is colored as red; otherwise, this element is colored as white.
The right color bar represents different miRNAs: miRNA oncogenes
(red), tumor suppressors (green), and other miRNAs (yellow).
doi:10.1371/journal.pone.0013067.g001
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has been reported that miRNAs have a lower SNP density than
their neighboring regions, consistent with the high overall
conservation of miRNAs. However, as the SNP patterns of
human p-mirsupps and p-oncomirs are unclear, we first mapped
the SNP data (dbSNP build 129) from UCSC [36] to human
miRNA precursors. Subsequent statistical analysis demonstrated
that p-mirsupps, p-oncomirs, and o-miRNAs show distinct
differences in SNP incidence. The p-mirsupps had the lowest
SNP incidence (8.1%, 3/37), followed by the p-oncomirs (19.2%,
5/26) and the o-miRNAs (34.3%, 219/638) (P=0.001, chi-square
test, File S3, Figure S1d). In addition, the p-mirsupps had a
lower SNP incidence (OR=0.42) than the p-oncomirs, although
the result was not significant (P=0.19, Fisher’s exact test), which
may be due to the small number of SNPs in both datasets.
Chromosome distribution of p-oncomirs and p-mirsupps
Genes are not randomly distributed on chromosomes [22].
miRNAs tend to form clusters on chromosomes [37] and the
distribution of miRNA genes is also nonrandom. In order to study
the chromosome distribution of p-oncomirs and p-mirsupps, we
first mapped all human miRNAs onto chromosomes (Figure S2).
Results showed that chromosome 14 had fewer than expected t-
miRNAs (P=0.002, randomization test), and chromosome 9
(P=0.03), 13(8/14, P=0.0002) and 21 (P=0.006) contained more
t-miRNAs than expected. There was a weak positive correlation
between the incidence of t-miRNAs and total miRNAs (R=0.36,
P=0.09, Spearman’s correlation). In addition, we also identified a
positive correlation between the incidence of p-oncomirs and p-
mirsupps (R=0.45, P=0.03, Spearman’s correlation), which
suggests that a high incidence of miRNA oncogenes is frequently
accompanied by a high incidence of miRNA tumor suppressors.
Therefore, this tendency to accompany each other at the
chromosome level warranted investigation into the presence or
absence of p-oncomir and p-mirsupp clustering and also raised the
question as to whether they are situated closely or distantly from
each other on the chromosome. To do this, we normalized the
length of each chromosome as one unit and classified all pairs of
miRNAs on a given chromosome into four groups: pairs consisting
of p-oncomirs and p-oncomirs (referred to as ‘‘onco-onco’’), pairs
of p-mirsupps and p-mirsupps (referred to as ‘‘supp-supp’’), pairs
of p-oncomirs and p-mirsupps (referred to as ‘‘onco-supp’’), and
pairs that did not belong to any of these first three types of pairs
(referred to as ‘‘other’’). We then calculated the distances between
miRNAs in all of the above pairs. It was of interest that these four
groups of pairs showed significantly different distances of
separation (P=5.49610
27, Kruskal-Wallis test, Figure 2). The
p-oncomirs tended to be clustered together. The p-mirsupps also
tended to be clustered together. However, the p-oncomirs and p-
mirsupps tended to be separated from each other (Figure 2). This
result indicates that at the chromosome level p-oncomirs and p-
mirsupps may cluster in different regions.
Calin et al. found that over half of the human miRNAs are
located in fragile sites and genomic regions involved in cancer
[37]. Based on their data, we counted the number of p-oncomirs
and p-mirsupps located in the deleted regions (DR) and in the
amplified regions (AR) in human cancer, respectively. The results
showed clear differences in distribution of p-oncomirs and p-
mirsupps in these two types of regions (P=0.001, Fisher’s exact
test). The p-oncomirs were more frequently found in amplified
regions (8AR vs. 5DR), while the p-mirsupps were more frequently
found in deleted regions (2AR vs. 21DR, File S4). This result
indicates that in human cancer p-oncomirs often gain function,
while p-mirsupps frequently lose function, which is consistent with
the overall concepts of oncogenesis and tumor-suppression,
respectively.
Expression of p-oncomirs and p-mirsupps
In a manner similar to protein-coding genes, miRNAs must
maintain a level of expression for proper function, and impaired
expression may result in diseases [7]. Although some character-
istics of miRNA expression such as tissue-specific expression [8]
have been described, understanding of p-oncomir and p-mirsupp
expression overall remains quite limited.
1. Tissue specificity. Previous studies have shown that
evolutionarily conserved protein-coding genes have a broad tissue
expression profile in mammals, insects, and plants [21]. This may
due to the fact that conserved genes are associated with functions
which are fundamental, and operate in diverse cellular conditions,
and are therefore expressed in more tissues [21]. We examined the
tissue specificity of p-oncomirs and p-mirsupps in normal tissues
based on the miRNA tissue specificity index (TSI) data used by Lu
et al. [38]. As expected, we found that t-miRNAs are more broadly
expressed than o-miRNAs (P=1.89610
25, Wilcoxon test). The p-
mirsupps showed a slightly greater breadth of expression than the
p-oncomirs (P=0.26, Wilcoxon test) but this difference was not
significant, and this failure to achieve significance may be due to
the small sample size of both miRNAs and tissues. Tissue
specificity is a relative concept as it is dependent in part on how
many tissues are used in a given study. As such, a significant
difference may be found in p-oncomirs and p-mirsupps when
expression data for more tissues becomes available.
2. Expression level. Figure 3 shows the expression level of p-
oncomirs, p-mirsupps, and o-miRNAs in 40 normal human tissues
based on the data of Liang et al. [39]. The p-mirsupps, p-
oncomirs, and o-miRNAs show significantly different expression
levels (P=8.01610
211, Kruskal-Wallis test, Figure 3). The p-
mirsupps have the highest expression levels in almost all of the 40
tissues, followed by p-oncomirs and o-miRNAs. Considering the
evolutionary conservation of p-mirsupps, p-oncomirs, and o-
miRNAs as analyzed earlier, this is analogous with previous studies
of protein-coding genes, wherein, expression level is correlated
with evolutionary conservation [21,40]. This observation is
Figure 2. Normalized distances on chromosomes of four
groups of miRNA pairs. Pairs of putative miRNA oncogenes (green),
pairs of putative miRNA tumor suppressors (red), pairs of putative
miRNA oncogenes and putative miRNA tumor suppressors (blue), and
other pairs that don’t belong to any of the first three groups (yellow).
doi:10.1371/journal.pone.0013067.g002
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functions are required to function in more cellular conditions and
more tissues, and therefore have more expression copies.
Targets of miRNAs
Maintaining a suitable expression level is critically important for
both miRNAs and protein-coding genes. The miRNAs have the
capacity to ‘‘tune’’ the expression of a target gene to a precise level
[41]. Therefore, investigation of target gene is one of the keys for
understanding miRNAs. In order to ensure accuracy in this
analysis, here we focused only on miRNAs with experimentally
validated targets.
1. Targets: tumor involvement? It is reasonable to suppose
that tumor associated miRNAs preferentially regulate tumor
associated protein-coding genes, and we thus evaluated t-
miRNA targets for association with tumors. Based on the listing
of miRNA targets in TarBase (version 5) [42], we found that
targets of p-mirsupps have the highest ratio of tumor involvement,
followed by p-oncimirs and o-miRNA (P=1.67610
212, chi-
square test, Figure 4a). Moreover, targets of t-miRNAs have a
higher ratio of tumor involvement than o-miRNAs (P=
3.8610
213, Fisher’s exact test) and targets of p-mirsupps have a
higher ratio of tumor involvement than p-oncomirs (P=0.03,
Fisher’s exact test).
2. Targets: oncogenes or tumor suppressors? Zhang et
al. speculated that miRNA oncogenes/tumor suppressors may
exert their function in cancer pathogenesis by regulating tumor
suppressors/oncogenes [15], but this could not be confirmed due
to the limited number of experimentally validated target at the
time of that report. Their hypothesis is supported by individual
evidence [18], however, no statistical analysis has been available.
Therefore, we performed an analysis of target oncogenes and
tumor suppressors of p-oncomirs and p-mirsupps based on the
data in TarBase [42]. As anticipated, p-oncomirs and p-mirsupps
showed clear differences, with p-oncomirs preferentially targeting
tumor suppressors, while p-mirsupps target oncogenes (P=0.025,
Fisher’s exact test, Figure 4b). This result gives statistical
confirmation to the speculation that tumor associated miRNAs
contribute to tumorigenesis by functional interactions with
oncogenes and tumor suppressors [18].
3. Targets: mechanisms of action. miRNAs typically
negatively regulate gene expression. Although the exact me-
chanisms through which miRNAs regulate gene expression
remains under debate, a simplified view of this regulation is that
miRNAs can inhibit translation or induce cleavage of target
mRNAs. Precise complementarity results in cleavage of target
mRNAs, while the binding of miRNAs and mRNAs with
mismatches leads to translation inhibition of target mRNAs
[8,43]. In animals, the cleavage of mRNAs by miRNAs
occasionally occurs but is much more unusual [43]. How
miRNAs oncogenes and tumor suppressors function remains
unknown, but understanding the mechanisms through which
miRNAs contribute to tumorigenesis is of clear importance. Here,
we classified miRNA-target actions into a cleavage group and an
inhibition group. Interestingly, p-oncomirs, p-mirsupps, and o-
miRNAs showed significantly different distribution in these two
groups (P=0.0004, chi-square test, Figure S3). There was a
significantly higher percentage (42.1%) of tumor-associated
miRNAs (t-miRNAs) in the cleavage group than o-miRNAs
(21.4%) (P=0.002, Fisher’s exact test). Of even greater interest,
over half (53.3%) of the actions between p-mirsupps and their
targets are of cleavage type, which is significantly higher than that
of p-oncomirs and their targets (25.8%) (P=0.01, Fisher’s exact
test). Further experiments are needed to determine why t-
Figure 3. Distribution of miRNA expression levels for putative
miRNA tumor suppressors (red), putative miRNA oncogenes
(green), and other miRNAs (yellow) across 40 normal human
tissues, shown as a box plot.
doi:10.1371/journal.pone.0013067.g003
Figure 4. Patterns of miRNA targets. (a) Tumor involvement of targets of putative miRNA oncogenes, putative miRNA tumor suppressors, and
other miRNAs. (b) Oncogene and suppressor distribution on targets of putative miRNA oncogenes and putative miRNA tumor suppressors.
doi:10.1371/journal.pone.0013067.g004
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mechanism, but we speculate that one possible reason may be that
translation inhibition confers potential danger for target mRNA
re-activation, whereas cleavage ensures target inactivation.
Although further experiments are needed to explore why tumor-
associated miRNAs, especially the miRNA tumor suppressors,
more frequently act by cleavage on their targets, this study
highlights the fact that different modes of action exist among
miRNAs and opens a door for studying the exact mechanisms by
which they contribute to tumorigenesis.
Size, free energy, transcription factors, and prediction
model of p-oncomirs and p-mirsupps
In this study, we also analyzed the molecular size, free energy,
and transcription factors of miRNA oncogenes and tumor
suppressors (File S5). In addition, a prediction model of p-
oncomirs and p-mirsupps was also established (File S5).
Discussion
This study not only identified putative human miRNA
oncogenes and tumor suppressors on a large scale but also greatly
expanded current knowledge about miRNAs and cancer. Features
of miRNA oncogenes and tumor suppressors which were analyzed
included function, evolutionary conservation, chromosomal distri-
bution, molecular size, free energy, transcription factor, and
targets. We found that miRNA oncogenes and tumor suppressors
show different patterns in most of the above features.
Perhaps of greatest importance, the patterns identified in this
study allow accurate classification of newly identified miRNAs as
p-oncomirs and p-mirsupps which function primarily in oncogen-
esis and tumor-suppression respectively. It is noteworthy that
miRNA oncogenes and tumor suppressors are not invariable in
their function but can switch function in some circumstance.
However, the model established in this study with the miRNA data
from before 2008 was tested with the data from after 2008 and
found to be consistent in classifying t-miRNAs. Nonetheless our
current knowledge of these molecules is in many ways still
rudimentary, however, if more data regarding novel cancer gene
mutations, genome methylation status and so on are integrated
into future studies, it is likely that our understanding of miRNA-
cancer associations will continue to grow.
Finally, we hope the data presented in this study will be a
resource for a wide range of research exploring both miRNAs and
cancer as many important issues remain to be considered in future
studies. One important issue is whether the role played by
miRNAs differs in different types of cancer. A second question is
that although it is clear that oncogenic miRNAs may act as tumor
suppressors and vice versa, when, where, and how do such
interchanges of role occur. Although it is not easy to answer such
questions, it is likely that their resolution will ultimately provide
great help in understanding the role of miRNAs in cancer. It is
also useful to note that the experimental confirmation of these
observations is of critical importance to determine how miRNAs
contribute to tumorigenesis. For example, regarding the mecha-
nism of action of miRNA oncogenes and suppressors, it is unclear
why the miRNA suppressors tend to abolish their target mRNAs
directly but not just inhibit their translation; and how the miRNA
suppressors achieve this.
Conclusion
In conclusion, although we are only beginning to understand
miRNA oncogenes and tumor suppressors in cancer, here we have
found significantly different patterns in miRNA oncogenes and
tumor suppressors. This study represents the first large-scale
analysis of human miRNA oncogenes and miRNA tumor
suppressors. The patterns identified in this study will provide help
in understanding of the roles miRNAs play in cancer, in the
identification of biomarkers for cancer diagnosis, prognosis, and
therapy, in the identification of novel miRNA oncogenes and
tumor suppressors, and in guiding biologic experimentation.
Materials and Methods
Identifying the human p-oncomirs and p-mirsupps
We identified human miRNAs either as p-oncomir or as p-
mirsupp by manually reviewing and culling nearly 5,000
publications. The decision rules for separating p-oncomirs and
p-mirsupp were as follows. If one (or more) paper clearly suggested
a given miRNA was a putative oncogene or tumor suppressor, we
assigned it to the p-oncomir or p-mirsupp group, respectively. If
no paper clearly suggested that a given miRNA was a putative
oncogene or tumor suppressor, it was designated as a p-oncomir
only if at least three different papers provided strong evidence that
the molecule in question was associated with up-regulation,
overexpression, and/or tumor growth; or designated as a p-
mirsupp if associated with down-regulation, underexpression,
and/or inhibition of tumor growth. In addition, assignments into
these two groups also required that no conflicts about the given
miRNA were found in literature. A few miRNAs were found
which evidently act as either oncogenes or tumor suppressors
depending on the context [44], and these were not assigned into
either the p-oncomir or p-mirsupp group. As a result, 84 miRNAs
were identified as putative oncogenes or tumor suppressors (File
S1). We further segregated these miRNAs into two groups. The
miRNAs identified from papers published before June 2008
comprised the first group, and this group was used to analyze the
p-oncomirs and p-mirsupps in this study. The miRNAs identified
from papers published between June 2008 and April 2009
comprised the second group, which was used as the testing dataset
for the miRNA oncogene and tumor suppressor prediction model.
It was important to determine how the miRNAs we identified in
this study cover the total set of human miRNA oncogenes and
tumor suppressors. Although it is difficult to estimate the coverage
of these miRNAs to the total number of miRNA oncogenes and
tumor suppressors, a simple estimation was made by comparing
miRNAs with protein-coding genes. Currently, ,700 miRNA
genes have been reported in humans (miRBase, May 2009) [30]
and it is estimated that there are ,1,000 miRNAs in the human
genome [7], and the p-oncomirs and p-mirsupps represent 8.4% of
the human miRNAs. According to a previous estimate based on
the tumor associated gene database (http://www.binfo.ncku.edu.
tw/TAG/), among the total ,30,000 protein-coding genes in the
human genome [45], only 1.24% (372) are oncogenes and tumor
suppressors. However, according to a much larger dataset
presented by Cui et al. [29], 7.1% (2128) of human protein-
coding genes are tumor associated. This percentage is similar to
that of the miRNAs (8.4%). Although it is difficult to make a more
specific evaluation of the coverage of the identified miRNA
oncogenes and tumor suppressors to the real total number of
miRNA oncogenes and tumor suppressors, this comparison is a
rough estimate that suggests our data is representative and can be
used for further analysis.
Data of miRNA targets, TFs, expression, deleted region
and amplified region involved in human cancers
To ensure the accuracy of this study, most of the data used in
this study have experimental supporting. We obtained the
Analysis of Cancer MicroRNAs
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[42], which also provides the data whether a target is involved in
tumor function and provides the data of miRNA-target regulatory
type (cleavage or repression). We obtained the human TF-miRNA
regulatory data from TransmiR (http://cmbi.bjmu.edu.cn/
transmir) [46], a database that integrated the experimentally
supported TF-miRNA regulatory data, which also provides that
data of TF action type (activation or repression) as well. We
obtained miRNA expression data across 40 normal human tissues
from Liang et al.’ study [39] and obtained the calculated miRNA
tissue specificity index value based on these data from Lu et al.’
study [38]. The deleted region and amplified region involved in
human cancers were obtained from Calin et al.’ study [37].
Reliability of evaluation of putative miRNA oncogenes
and tumor suppressors used in the analysis
In order to evaluate the reliability and accuracy of the
categorization of the putative miRNA oncogenes and tumor
suppressors used in the analysis. Five aspects of the categorization
of p-oncomirs and p-suppmirs culled in this study were evaluated.
1. Genomic regions of p-oncomirs and p-suppmirs. As
demonstrated previously, we found that p-oncomirs and p-
suppmirs are located mainly in the amplified regions and deleted
regions respectively in human cancers (P=0.001, Fisher’s exact
test), which suggests that the miRNAs we examined are indeed
expressed in the oncogenic regions and tumor-suppressing regions.
2. Targets of the p-oncomirs and the p-suppmirs. In the
previous sections, we showed that p-oncomirs mainly regulate
tumor suppressors, and p-suppmirs mainly regulate oncogenes
(P=0.025, Fisher’s exact test). This result was consistent with the
hypothesis that miRNA oncogenes and tumor suppressors
preferentially interact with tumor suppressors and oncogenes,
respectively, and further supported categorization of the p-
oncomirs and p-mirsupps used for this study.
3. Transcription factors that regulate p-oncomirs and p-
mirsupps. This high percentage of balanced TF-miRNA
(85.8%) regulations (File S5) represents qualitative evidence that
the p-oncomirs and p-mirsupps are accurately assigned into these
groups.
4. Further review of the literature regarding the p-
oncomirs and the p-mirsupps used in this analysis. In
this study, for initial analysis we used p-oncomirs and p-mirsupps
culled from literature published before June 2008. We later
confirmed the roles of these miRNAs using literature published
from June 2008 and April 2009. We found that 93.7% (59/63) of
the functional descriptions of these culled miRNAs were
consistently maintained over both periods. The four exceptions
were mir-16-1, mir-17, mir-181b-1, and mir-181b-2. As a putative
miRNA oncogene, most of the new literature supports up-
regulation of miR-17-5p in cancers but Cloonan et al. reported
that it may act as a suppressor in some situations [47]. As a
putative miRNA tumor suppressor, miR-16 was reported to be up-
regulated in malignant renal cell cancer compared to a non-
malignant kidney tumor and was also up-regulated in cervical
cancer [48]. miR-181b was reported to show increased expression
in early onset colorectal carcinoma [49]. Considering the fact that
the oncogenic and the tumor-suppressing process are
interchangeable in specific cases [29], the above exceptions are
reasonable and acceptable. Thus, although there were some
exceptions exist, the categorization of the majority (93.7%) of these
miRNAs has remained unchanged.
5. Prediction of novel p-oncomirs and p-mirsupps. Most
importantly, if these p-oncomirs and p-mirsupps are
representative, the patterns identified based on these miRNAs
should have strong predictive value for categorization of novel p-
oncomirs and p-mirsupps. In fact, our prediction model achieved
an accuracy of 85.7% in discrimination of novel p-oncomirs from
p-mirsupps (File S1 & File S5). This result suggests that the p-
oncomirs and p-mirsupps we culled from earlier literature are
representative of oncogenes and suppressors. In conclusion, based
on the above evaluations of these five aspects of p-oncomirs and p-
mirsupps, we conclude that the p-oncomirs and the p-mirsupps
used for this analysis were categorized correctly.
Statistical analysis
Statistical computing and test were carried out using R, a
statistical computing language (http://www.r-project.org/). We
performed randomization tests to evaluate the statistical signifi-
cance of enrichment of tumor-associated miRNAs on chromo-
somes by randomly permuting the distributions of tumor-
associated miRNAs on chromosomes 5,000 times and comparing
the random number of tumor-associated miRNAs on a given
chromosome with the real number of tumor-associated miRNAs
on this chromosome.
Supporting Information
Figure S1 Conservation evaluation of miRNAs. (a) Comparison
of cross-species conservation between tumor-associated miRNA
and other miRNAs. (b) Comparison of cross-species conservation
between putative miRNA oncogenes and miRNA tumor suppres-
sors. (c) Incidences of miRNA duplicates in putative miRNA
oncogenes, miRNA tumor suppressors, and other miRNAs. (d)
Incidences of SNPs in putative miRNA oncogenes, miRNA tumor
suppressors, and other miRNAs.
Found at: doi:10.1371/journal.pone.0013067.s001 (1.53 MB
TIF)
Figure S2 Chromosome distribution of putative miRNA
oncogenes, miRNA tumor suppressors and other miRNAs. Each
gray vertical bar represents one chromosome. MiRNAs in
chromosomes are highlighted as colored lines, putative miRNA
oncogenes (green), miRNA tumor suppressors (red), and other
miRNAs (yellow).
Found at: doi:10.1371/journal.pone.0013067.s002 (0.93 MB TIF)
Figure S3 Incidence of cleavage action on targets of putative
miRNA oncogenes, putative miRNA tumor suppressors, and other
miRNAs.
Found at: doi:10.1371/journal.pone.0013067.s003 (0.37 MB
TIF)
File S1 Information of miRNA oncogenes and tumor suppres-
sors used in this study.
Found at: doi:10.1371/journal.pone.0013067.s004 (0.26 MB
DOC)
File S2 Cross-species conservation of human miRNAs.
Found at: doi:10.1371/journal.pone.0013067.s005 (0.69 MB
DOC)
File S3 Distribution of SNPs in human miRNAs.
Found at: doi:10.1371/journal.pone.0013067.s006 (0.23 MB
DOC)
File S4 Distribution of miRNA oncogenes and tumor suppres-
sors on chromosome regions associated with human cancer. "D"
represents deleted regions in cancer and "A" represents amplified
regions in cancer.
Found at: doi:10.1371/journal.pone.0013067.s007 (0.05 MB
DOC)
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